Peptides Gain Traction in Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Peptides Gain Traction in Drug Development
Although representing a small part of overall drug development, peptides and related technologies to improve their production are making inroads.


Pharmaceutical Technology Europe
Volume 24, Issue 6

Other approaches. In 2011, the biopharmaceutical company Sutro Biopharma formed a multiyear collaboration with Pfizer for the research, development and commercialisation of novel peptidebased therapeutics. The partnership gives Pfizer access to peptides that have been difficult to produce using conventional technologies using a biochemical protein synthesis technology platform developed by Sutro. In 2008, Pfizer acquired CovX, a biopharmaceutical company with a technology platform that links therapeutic peptides to an antibody scaffold. The peptide targets the disease while the antibody scaffold allows the peptide to remain in the body long enough to achieve therapeutic benefit. The technology thereby allows for better half-life extension and bioavailability to support optimal dosing regimens for peptide therapeutics.

References

1. T. Sawyer, Chem. Biol. Drug. Des. 73 (1), 3–6 (2009).

2. W. Wolfson, Chem. & Biol. 16 (9), 910–911 (2009).

3. Peptide Therapeutics Foundation, Development Trends for Peptide Therapeutics Report (San Diego, 2010).

4. FDA, Copaxone Label (Feb. 27, 2009), Drugs@FDA, accessed May 15, 2012.

5. FDA, Lupron Label (Mar. 28, 2012), Drugs@FDA, accessed May 15, 2012.

6. FDA, Zoladex Label (Jan. 14, 2011), Drugs@FDA, accessed May 15, 2012.

7. FDA, Sandostain Label (Mar. 23, 2012), Drugs@FDA, accessed May 15, 2012.

8. FDA, Byetta Label (Oct. 19, 2011), Drugs@FDA, accessed May 15, 2012.

9. FDA, Forteo Label (July 26, 2009), Drugs@FDA, accessed May 15, 2012.

10. P. Van Arnum, Pharm. Technol. 35 (5), 56–60 (2011).

11. S. Bhattacharya et al., Biopolymers 97 (5), 253–264 (2012).

12. D. Ly et al., J. Am. Chem. Soc. 134 (9), 4041–4044 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here